Key Takeaways
- Buprenorphine is a partial opioid agonist, and its effect flattens out at higher doses, which is why its labels describe a ceiling effect.
- The methadone label carries a boxed warning for life-threatening respiratory depression and for a dangerous heart-rhythm change.
- Buprenorphine is the lower-risk opioid, not a risk-free one, and its own labels warn about chronic lung disease, older age, and the days after a dose change.
- Combining any opioid with a benzodiazepine or alcohol removes much of buprenorphine’s advantage.
- Butrans and Belbuca are the buprenorphine products approved for pain, while Suboxone is approved for opioid dependence, and a pain patient on a daily full opioid is already physically dependent, which is the condition that approval covers.
- In my experience, the buprenorphine dose can come down over time while pain stays controlled, which I do not see with full opioids.
- Many pain patients became physically dependent by taking exactly what was prescribed, and physical dependence is a medical condition, not an addiction.
Is buprenorphine safer for a pain patient who has trouble breathing?
Yes, buprenorphine is less dangerous for your breathing than a full opioid such as oxycodone, morphine, or methadone. That is the plain answer, and it comes with real limits that I will get to.
This article is for the person with chronic pain who also has sleep apnea, chronic obstructive pulmonary disease (COPD), asthma, or a chest that never fully recovered from an illness. You are taking a full opioid, or someone is offering you one, and you want pain control with a wider margin for error.
There is a second question hiding behind the first. If you switched to buprenorphine, could the dose ever come down without the pain coming back? Both questions have answers, and the second one is the more interesting of the two.
Why does a full opioid slow your breathing, and why does buprenorphine stop short?
Opioids act on a receptor that sits, among other places, in the part of the brainstem that tells you to breathe. Think of that receptor as a dimmer switch. A full agonist, which is the name for a drug that can turn the switch all the way, keeps turning it as the dose goes up, and breathing slows with it.
Buprenorphine is a partial agonist. It turns the switch part of the way and then stops, no matter how much more is taken. The Belbuca label puts it this way: “Unlike other opioids, buprenorphine appears to exhibit a dose-ceiling effect.” The Suboxone label says that sublingual buprenorphine “produces typical opioid agonist effects which are limited by a ceiling effect.”
Years ago, I wrote that buprenorphine is the broccoli of opioids. You can eat a second helping of broccoli, and a third, and you will feel no different than you did after the first. Nobody is breaking into a pharmacy for broccoli.
While this is not a perfect analogy, it explains why few people chase a high from buprenorphine and why its effect on breathing flattens out. The full agonists keep going. Buprenorphine does not.
What does the methadone label say about breathing?
Methadone is a long-acting opioid that pain clinics do prescribe, so it is a fair comparison. Its label opens with a boxed warning titled “LIFE-THREATENING RESPIRATORY DEPRESSION, LIFE-THREATENING QT PROLONGATION.” A boxed warning is literally a box at the top of the prescribing information, and it is the strongest warning the United States Food and Drug Administration (FDA) requires.
Inside that box, the methadone label states that “Fatal respiratory depression may occur, with highest risk at initiation and with dose increases.” It adds a warning that is particular to methadone: “The peak respiratory depressant effect of methadone occurs later, and persists longer than the peak pharmacologic effect, especially during the initial dosing period.” In plain words, the pain relief wears off before the breathing effect does, which is exactly the wrong order for a person with weak lungs.
The second half of the box is about the heart. The label states that “QT interval prolongation and serious arrhythmia (torsades de pointes) have occurred during treatment with methadone.” The QT interval is a measurement on an electrocardiogram, and when it stretches too far, the heart can fall into a dangerous rhythm.
Methadone has its place, and some people do well on it for years. I have written before about the differences between methadone and buprenorphine and about why I do not provide methadone maintenance treatment. The point here is relative risk, not that methadone is a bad drug. For breathing, the margin is narrower.
What do the buprenorphine labels still warn about?
This is the section that keeps the article honest. The Belbuca label, in the same words as the Butrans label, warns that “Serious, life-threatening, or fatal respiratory depression may occur, especially during initiation or following a dosage increase.” A ceiling is not a floor. The effect flattens out at higher doses, but it does not vanish at lower ones.
Unfortunately, the labels also carry a warning aimed squarely at the reader of this article. The Butrans label carries a separate warning for life-threatening respiratory depression in patients with chronic pulmonary disease, and in patients who are older, severely underweight, or debilitated by illness. If you have COPD, if you are older, or if disease has taken a great deal of your weight, the label singles you out.
So, is buprenorphine safe for a person with lung disease? No opioid is safe for a person with lung disease. Buprenorphine is the less dangerous one, and the difference is a wider margin, not a guarantee.
Benzodiazepines and alcohol erase most of the advantage.
Many of my pain patients were also prescribed a benzodiazepine somewhere along the way, for sleep, for anxiety, or for muscle spasm. The labels have something specific to say about that combination. The Belbuca label, and the Butrans label in the same words, reports that in laboratory work the combination of benzodiazepines and buprenorphine “altered the usual ceiling effect on buprenorphine-induced respiratory depression, making the respiratory effects of buprenorphine appear similar to those of full opioid agonists.”
Read that sentence twice. A benzodiazepine turns the broccoli back into a full opioid. The label goes on, in words that also appear in the methadone label: “Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.”
The Suboxone label adds that “Many, but not all, postmarketing reports regarding coma and death involved misuse by self-injection or were associated with the concomitant use of buprenorphine and benzodiazepines or other CNS depressants, including alcohol.” This is the combination that erases buprenorphine’s advantage, and it is common in pain patients. It is the first thing I ask about.
Which buprenorphine products are approved for pain?
Two of them. Butrans is a skin patch, and Belbuca is a film held inside the cheek. The Belbuca label states that “BELBUCA is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids.”
Suboxone, the film placed under the tongue, is a different story. Its label states that “SUBOXONE sublingual film is indicated for treatment of opioid dependence.” Some physicians use it off label for pain, and off label simply means that the FDA approved the drug for one purpose and the doctor is prescribing it for another, which is legal and common.
There is a point here that is easy to miss. A person who has taken a full opioid for pain every day for months or years is physically dependent on it, which the Butrans label describes as something that “may not occur to a clinically significant degree until after several days to weeks of continued use.” That dependence is the condition buprenorphine is approved to treat. So the pain patient who would do well on buprenorphine is usually not asking for an off-label drug at all; the on-label use fits them already, and the pain relief comes with it.
In my practice, I treat opioid dependence with buprenorphine by telemedicine in Florida, with office visits available in Fort Lauderdale. Buprenorphine for pain is a different decision, with a different label and a different set of questions, and it belongs with your pain doctor. What I can do is advise you in a consultation on the options, the trade-offs, and the questions to bring to that doctor.
Can the dose come down without the pain coming back?
My answer here comes from clinical experience rather than from a label. The Butrans label defines tolerance as “the need for increasing doses of opioids to maintain a defined effect.” With full opioids, that is the pattern I have watched for many years: the dose climbs, the relief does not keep up, and the climbing dose brings the breathing risk closer.
In my practice, people on buprenorphine for pain tend not to need ever-rising doses. The effect flattens, tolerance builds slowly if at all, and the dose can often be brought down over time while the pain stays controlled. I do not see that with full opioids, and I cannot give you a number for it, because it is a pattern I have observed, not a figure anyone has measured.
Brought down never means stopped abruptly. A taper is gradual and patient directed, with holds whenever the pain or the withdrawal symptoms say that the last step was too big. If a reduction is too much, your doctor must slow it down, and if it is going well, you and your doctor may agree to go a bit faster, as tolerated.
Many pain patients became physically dependent on opioids by taking exactly what their doctor prescribed. That is a medical condition caused by a medication, and dependence is not addiction. If you are wondering what else you can take alongside buprenorphine, I have covered which pain medicines can be taken with Suboxone in a separate article.
Is buprenorphine strong enough for severe pain?
The Belbuca label answers this directly, since the product is indicated for “severe and persistent pain that requires an opioid analgesic.” A ceiling on breathing is not the same as a ceiling on pain relief, and for many patients the relief holds up well. Whether it is enough for one particular person is a question for that person’s prescriber.
Can someone on buprenorphine for pain switch back to a full opioid?
That is a question for the prescriber, and the timing matters in both directions. The buprenorphine labels caution that a partial agonist started in a person who is still taking a full opioid can reduce pain relief or set off withdrawal. Going either way is a planned handoff, never a swap made at home.
Does taking buprenorphine mean a patient will be refused surgery or anesthesia?
No. Buprenorphine is a reason to plan, not a reason to be turned away. In Dr. Leeds’ experience, the surgical and anesthesia team needs to know well ahead of time, so that pain control around the operation is worked out among the patient, the surgeon, and the prescriber.
If someone taking an opioid has slow or stopped breathing, blue lips, or cannot be woken, call 911.
If you have chronic pain and lungs that cannot afford a mistake, buprenorphine deserves a place in the conversation with your pain doctor. Dr. Leeds treats opioid dependence with buprenorphine by telemedicine throughout Florida and can advise on buprenorphine options for pain in a consultation. Contact Dr. Leeds today to ask about a consultation.
This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.
